Market closedADR
Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
649
Website
AUTL Metrics
BasicAdvanced
$357M
-
-$0.86
2.06
-
Price and volume
Market cap
$357M
Beta
2.06
52-week high
$2.13
52-week low
$1.11
Average daily volume
1.7M
Financial strength
Current ratio
10.881
Quick ratio
10.475
Long term debt to equity
68.854
Total debt to equity
69.556
Interest coverage (TTM)
-25.91%
Management effectiveness
Return on assets (TTM)
-25.99%
Return on equity (TTM)
-81.91%
Valuation
Price to revenue (TTM)
33.786
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-1.418
Growth
Revenue change (TTM)
496.00%
Earnings per share change (TTM)
-27.81%
3-year revenue growth (CAGR)
63.16%
3-year earnings per share growth (CAGR)
-24.02%
AUTL News
AllArticlesVideos
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·2 weeks ago
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
GlobeNewsWire·2 weeks ago
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $357M as of April 16, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of April 16, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.